Natural products derived from fungi have a glorious pedigree in alleviating human suffering, with penicillins being the very first microbially derived compounds to be clinically used as antibiotics. Beyond the antibiotic activity of penicillins and contemporary cephalosporins, fungal natural products exhibit extensive utility in a myriad of clinical applications. Among these, fungal polyketides offer a vast array of bioactive molecules with prominent examples including the cholesterol-lowering lovastatin, immunosuppressant mycophenolic acid, and angiogenesis inhibitor cytochalasin E (1-3). Although polyketide natural products possess a comparatively higher "hit rate" for drug development (0.3%) compared with synthetic high-throughput screening libraries (<0.001%) (4), their complicated chemical structures that contain multiple stereocenters and numerous oxygencontaining substituents complicate synthetic diversity-oriented modifications (5). This structural complexity has precipitated the need to expand the chemical space naturally explored in microbes through the genetic reprogramming of secondary metabolism to yield designer molecules. Engineering of natural products via coexpression of heterologous gene combinations has been realized for bacterial polyketide antibiotics (6, 7). In PNAS, Xu et al. (8) extend this paradigm for a class of fungal polyketide natural products called the benzenediol lactones (BDLs) and generate novel "nonnatural" natural products while also providing means to generate previously described minor analogs in much improved yields.
BDLs are chemically interesting compounds possessing a dihydroxyphenyl ring fused to a macrolactone ring (Fig. 1 ). These fungal polyketide natural products exhibit numerous desirable bioactivities that include the estrogen agonist zearalenone, heat shock response modulators radicicol and monocillin II, and mammalian immune response regulator 10,11-dehydrocurvularin (1). BDLs are synthesized by the tandem action of two cooperative fungal iterative polyketide synthase (iPKS) assembly line enzymes comprising highly reducing (hrPKS) (9) and nonreducing (nrPKS) modules (10) . The hrPKS acts first and constructs the lipid fragment that gets transferred to the nrPKS for further biosynthetic processing to install the aromatic fragment (Fig. 1) . As more and more BDL structures and their associated biosynthetic gene clusters are revealed (11), a straightforward bioengineering approach to expand the chemical space naturally explored by BDL structures was envisaged by Xu et al. (8) to recombine unnatural pairs of BDL hrPKS and nrPKS elements. A major knowledge gap prior to this study by Xu et 
The Molnar group previously explored individual iPKS domain engineering and swapping approaches, such as for the product template (PT) (12) and thioesterase (TE) (13) domains between radicicol/monocillin II nrPKSs from Chaetomium chiversii (CcRad) (14) and 10,11-dehydrocurvularin nrPKS from Aspergillus terreus (AtCur) (15) . Further building on the impressive body of work compiled by the Tang and Vederas laboratories on fungal iPKS systems (9, 16, 17) , in the present study, Xu et al. take a significant step forward and explore how structural diversity for BDLs can be generated by pairwise combination of hrPKS and nrPKS modules derived from four different BDL biosynthetic gene clusters. In addition to CcRad and AtCur gene loci, they further expand their approach to include the newly discovered lasiodiplodin and resorcylide biosynthetic iPKSs from Lasiodiplodia theobromae (LtLas) and Acremonium zeae (AzRes), respectively (11) , to provide 16 possible hrPKS-nrPKS combinations.
Most gratifyingly, the authors observe that polyketide intermediates can be shuttled between orthologous hrPKS-nrPKS pairs. Although this observation preserves the vectorial PKS hypothesis (18) , it offers a significant step forward in the module-swapping type of surgical engineering of PKSs (4). This seminal finding makes accessible a vast chemical space to combinatorially assemble BDLs with simultaneous alterations at both the aromatic and lipid macrocycle cores. Based on the rich dataset obtained from 16 hrPKS-nrPKS combination experiments, the authors report that unnatural pairs of BDL biosynthetic iPKSs can often work synergistically. For instance, nrPKSs were found to be generally accommodating toward noncognate hrPKS intermediates that were equal or greater in chain length than their cognate hrPKS products. However, if these enzymatic compensations deviated too much against the natural pathway, then downstream processing events such as offloading and macrocyclization were impeded to yield byproducts rather than the cognate natural products.
These findings illustrate that even the cross-talk between highly related iPKS pairs can be rather fickle. They further illuminate significant shortcomings in our current understanding of polyketide biosynthesis about the intimate interplay between assembly line proteins and their covalently bound biosynthetic intermediates. Tremendous insight has been achieved with high-resolution structures of the complete fungal fatty acid synthase (19) and recently for bacterial PKS modules (20, 21) that begin to resolve the mechanistic decision-making process of these multifunctional enzymes. Such structural efforts in combination with prior (12, 13) and current (8) genetic reprogramming studies, such as those by Xu et al., are together contributing toward a clearer mechanistic understanding of PKS design rules that will undoubtedly facilitate how they can be tweaked to generate even greater chemical diversity.
